Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
1. Moderna secured a $590 million U.S. government grant for vaccine development. 2. Positive results reported for mRNA-1018 in Phase 1/2 trials. 3. Phase 3 trials for mRNA-1018 are set to begin soon. 4. Bird flu outbreaks in poultry are causing production issues. 5. Moderna stock remains down 65% year-over-year despite recent gains.